Prolongation of rat kidney allograft survival by nematodes

Transplantation
D L LedinghamT D Lee

Abstract

Nippostrongylus infection strongly stimulates TH2 activity in vivo. Given the evidence of cross regulation between TH2 and TH1 cells, and the link between TH1 activity and graft rejection, we examined the effects of Nippostrongylus infection on the fate of kidney allografts in rats. Both prior Nippostrongylus infection and prior treatment with a soluble worm product significantly delayed kidney allograft rejection. Control graft rejection occurred at 9.7 +/- 1.2 days whereas grafts in Nippostrongylus- or worm extract-treated recipients lasted 32.7 +/- 11.3 days and 21.5 +/- 4.6 days, respectively. At day 5 posttransplant mononuclear cell infiltration was much reduced in the Nippostrongylus-treated recipients. Flow cytometry of isolated graft-infiltrating leukocytes showed a marked decrease in infiltrating T cells (82.8% reduction) with both CD4+ cells (81.0% reduction) and CD8+ cells (84.6% reduction) being reduced. CD8+ T cells, in particular, made up a much smaller proportion of the graft-infiltrating cells (22% rather than 49%) in the Nippostrongylus-treated animals as compared with untreated controls. Immunohistochemical assay of the graft tissue confirmed the flow cytometric results. Interleukin 4 expression was clearly de...Continue Reading

References

Feb 1, 1987·The Journal of Experimental Medicine·M J DallmanP J Morris
Jun 1, 1995·The Journal of Allergy and Clinical Immunology·T D Lee, C Y Xie
Jun 1, 1993·Immunology Today·F Powrie, R L Coffman
Jan 1, 1993·International Archives of Allergy and Immunology·T D Lee, A McGibbon
Jun 1, 1963·Experimental Parasitology·F W JENNINGSG M URQUHART
Jan 1, 1987·Immunology Today·T R Mosmann, R L Coffman

❮ Previous
Next ❯

Citations

Jun 17, 2005·Springer Seminars in Immunopathology·Joel V WeinstockDavid E Elliott
Jan 22, 2005·Current Allergy and Asthma Reports·Hermelijn H SmitsMaria Yazdanbakhsh
Aug 11, 2000·Transplantation Proceedings·H XuL L Bailey
Dec 5, 1998·Transplantation Proceedings·T NemotoT Nagao
May 15, 2002·Immunology Letters·Diane L SewellZsuzsa Fabry
Jul 2, 2005·Journal of Pediatric Gastroenterology and Nutrition·Qian Yuan, W Allan Walker
Oct 5, 2012·Clinical Microbiology Reviews·Henry J McSorley, Rick M Maizels
Oct 16, 2002·Infection and Immunity·W I KhanS M Collins
Sep 13, 2013·Transplantation·Chris J C JohnstonRick M Maizels
Sep 24, 2005·Parasite Immunology·K J Else
Jan 16, 2004·Alimentary Pharmacology & Therapeutics·M M Hunter, D M McKay
Apr 26, 2008·Transplant International : Official Journal of the European Society for Organ Transplantation·Juan ZhouBjorn A P Nashan
Jul 25, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Irina LeonardiGerhard Rogler
Sep 23, 2003·The American Journal of Gastroenterology·Robert W SummersJoel V Weinstock
Sep 7, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D E ElliottJ V Weinstock
Jun 22, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J ZhouT D Lee
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Agnès BoitelleCatherine E Lawrence
Nov 15, 2002·American Journal of Physiology. Gastrointestinal and Liver Physiology·David E ElliottJoel V Weinstock
May 14, 2021·Transplantation·Kyle T Cunningham, Kingston H G Mills

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.